Furthermore, SIRT4 is functionally sufficient and indispensable to promote TIC properties of pancreatic cancer cells by directly deacetylating ENO1 at K358, leading to attenuated ENO1's RNA‐binding capacity, enhanced glycolytic substrate 2‐PG affinity, and subsequently robust catalytic activity with boosted glycolytic ability and increased production of lactate acid. Here, SIRT4 is linked to familial pancreatic carcinoma.